Cytochrome P450 polymorphisms in geriatric patients - Impact on adverse drug reactions - A pilot study

被引:13
|
作者
Egger, T
Dormann, H
Ahne, G
Pahl, A
Runge, U
Azaz-Livshits, T
Neubert, A
Criegee-Rieck, M
Gassmann, KG
Brune, K
机构
[1] Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, Erlangen, Germany
[2] Univ Erlangen Nurnberg, Dept Internal Med, Erlangen, Germany
[3] Waldkrankenhaus St Marien, Dept Geriatr Rehabil, Erlangen, Germany
[4] Hadassah Hebrew Univ, Ctr Med, Dept Clin Pharmacol, Jerusalem, Israel
关键词
D O I
10.2165/00002512-200522030-00007
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background and objective: Up to 23% of the population, depending on their ethnic background, has genetically determined differences in the metabolism of drugs by the cytochrome P450 (CYP) enzymes CYP2C9, CYP2C19 and CYP2D6. The aim of this survey was to determine the relationship between genetical polymorphisms in these CYP enzymes and adverse drug reactions (ADRs) in geriatric patients. Study design: In a prospective 6-month cohort study of 243 patients in a geriatric rehabilitation ward, mean age 80.2 +/- 7.7 years, ADRs were identified by intensive monitoring by a pharmacoepidemiological team, consisting of pharmacists and physicians. 125 out of these 243 patients were genotyped cross-sectionally for polymorphisms of CYP2C9, CYP2C19 and CYP2D6 by the TaqMan-polymerase chain reaction. The main outcome measures were the prevalence of genetical polymorphisms and the patients' risk for developing an ADR as related to the genotype. Results: Patients received an average of 14.2 drugs during hospitalisation which led to 251 ADRs in the whole cohort and 149 ADRs in the cross-sectional genotyping study. Genotype frequencies of CYP2C9 enzyme were 25.9% (n = 29) intermediate metabolisers (IMs) and 2.7% (n = 3) poor metabolisers (PMs). For the enzyme CYP2C19,26.8% (n = 33) IMs and 0.8% (n = 1) PMs were detected. For the enzyme CYP2D6, 24.1% (n = 26) IMs and 3.7% (n = 4) PMs were found in the analysed patient population. In total, 61.6% (n = 77) of genotyped patients experienced mutations in at least one of the three cytochrome enzymes. The ADR rate did not differ significantly between patients with genetic mutations and wild-type genotype patients. Moreover, only eight out of 40 ADRs which were associated with drugs metabolised by CYP2C9, CYP2C19 or CYP2D6 were detected in patients with IM genotype and none in patients with PM genotype. Conclusion: In this investigation geriatric patients showed a high rate of ADRs. However, no association between the ADR rate and the patients' genotype could be detected, which most likely was a result of the small number of patient samples analysed. Although prophylactic genotyping would have not prevented ADRs in this pilot study, physicians nevertheless have to be aware of potential genetic mutations in patients with polypharmacy.
引用
收藏
页码:265 / 272
页数:8
相关论文
共 50 条
  • [1] Cytochrome P450 Polymorphisms in Geriatric PatientsImpact on Adverse Drug Reactions — A Pilot Study
    Tobias Egger
    Harald Dormann
    Gabi Ahne
    Andreas Pahl
    Ulrich Runge
    Tanya Azaz-Livshits
    Antje Neubert
    Manfred Criegee-Rieck
    Karl G. Gassmann
    Kay Brune
    [J]. Drugs & Aging, 2005, 22 : 265 - 272
  • [2] Cytochrome P450 enzyme polymorphisms and adverse drug reactions
    Pirmohamed, M
    Park, BK
    [J]. TOXICOLOGY, 2003, 192 (01) : 23 - 32
  • [3] P450 polymorphisms and adverse drug reactions
    Pirmohamed, M
    [J]. TOXICOLOGY, 2003, 192 (01) : 55 - 56
  • [4] Identification of Cytochrome P450 Polymorphisms in Burn Patients and Impact on Fentanyl Pharmacokinetics: A Pilot Study
    Grimsrud, Kristin N.
    Ivanova, Xenia
    Sherwin, Catherine M.
    Palmieri, Tina L.
    Tran, Nam K.
    [J]. JOURNAL OF BURN CARE & RESEARCH, 2019, 40 (01): : 91 - 96
  • [5] Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions
    Beibei Gao
    Tingfei Tan
    Xi Cao
    Menglu Pan
    Chunlan Yang
    Jianxiong Wang
    Zongwen Shuai
    Quan Xia
    [J]. BMC Medical Genomics, 15
  • [6] Relationship of cytochrome P450 gene polymorphisms with blood concentrations of hydroxychloroquine and its metabolites and adverse drug reactions
    Gao, Beibei
    Tan, Tingfei
    Cao, Xi
    Pan, Menglu
    Yang, Chunlan
    Wang, Jianxiong
    Shuai, Zongwen
    Xia, Quan
    [J]. BMC MEDICAL GENOMICS, 2022, 15 (01)
  • [7] Cytochrome P450 polymorphisms and the individualization of drug treatment
    Daly, AK
    [J]. DRUG METABOLISM REVIEWS, 2003, 35 : 21 - 21
  • [8] Polymorphisms of cytochrome p450 and adverse events of tamoxifen therapy
    Ignatova, A.
    Zacharenkova, J.
    Dudina, I.
    Savelyeva, M.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 : S20 - S21
  • [9] Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug–drug interactions: a PharmacoVigilance study in France
    Anne Charlotte Danton
    François Montastruc
    Agnès Sommet
    Geneviève Durrieu
    Haleh Bagheri
    Emmanuelle Bondon-Guitton
    Maryse Lapeyre-Mestre
    Jean-Louis Montastruc
    [J]. European Journal of Clinical Pharmacology, 2013, 69 : 885 - 888
  • [10] Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions: a PharmacoVigilance study in France
    Danton, Anne Charlotte
    Montastruc, Francois
    Sommet, Agnes
    Durrieu, Genevieve
    Bagheri, Haleh
    Bondon-Guitton, Emmanuelle
    Lapeyre-Mestre, Maryse
    Montastruc, Jean-Louis
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (04) : 885 - 888